Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)
Condition: Breast Carcinoma Intervention: Other: Non-Interventional Study Sponsor: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Handheld Ultrasound Device to Triage Women With a Positive Clinical Breast Examination by Trained Non-radiologists
Conditions: Breast Cancer; Carcinoma in Situ Interventions: Other: Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists. Sponsors: International Agency for Research on Cancer; Malabar Cancer Care Society Kannur, India; Bhabha Atomic Research Centre (BARC), India Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)
Conditions: Breast Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
Conditions: Breast Neoplasms; Breast Cancer; Early-stage Breast Cancer; Non-Metastatic Breast Carcinoma; Polyneuropathy Due to Drugs; Polyneuropathy; Drug; Chemotherapy-induced Peripheral Neuropathy; Quality of Life Interventions: Device: Garmin smartwatch; Other: REBECCA Mobile application; Other: REBECCA PC plug-in Sponsors: Theodoros Foukakis; Karolinska Institutet; Centre for Research and Technology Hellas (CERTH) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
Conditions: Breast Neoplasms; Breast Cancer; Early-stage Breast Cancer; Non-Metastatic Breast Carcinoma; Polyneuropathy Due to Drugs; Polyneuropathy; Drug; Chemotherapy-induced Peripheral Neuropathy; Quality of Life Interventions: Device: Garmin smartwatch; Other: REBECCA Mobile application; Other: REBECCA PC plug-in Sponsors: Theodoros Foukakis; Karolinska Institutet; Centre for Research and Technology Hellas (CERTH) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
Conditions: Triple Negative Breast Cancer; Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Head and Neck Cancer; Colorectal Cancer; Non-small Cell Lung Cancer Interventions: Drug: BDC-3042; Drug: Pembrolizumab Sponsors: Bolt Biotherapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
EMBRACE: Exercising Together
Conditions: Breast Carcinoma; Prostate Carcinoma Interventions: Other: Exercise Intervention; Procedure: Biospecimen Collection; Other: Educational Intervention Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Other: Medical Chart Review; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Other: Medical Chart Review; Other: Questionnaire Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
